Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy

Summary

The purpose of this study is to determine etokimab safety, tolerability and activity in adult participants with peanut allergy.

Timeline

Start

2017-01-26

Primary completion

2018-03-30

Completion

2018-03-30

Outcome

Missed primary endpoint

registry analysis (superiority test); Etokimab vs Placebo; p = 0.463; Least Squares (LS) Mean Difference 60.046 (95% CI -108.566 to 228.657); ANCOVA NCT02920021 ↗

Publications

• Results Chinthrajah S, Cao S, Liu C, Lyu SC, Sindher SB, Long A, Sampath V, Petroni D, Londei M, Nadeau KC. Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy. JCI Insight. 2019 Nov 14;4(22):e131347. doi: 10.1172/jci.insight.131347.

Drugs

Indications